Haymarket takes over oncology titles

Haymarket Medical has taken over the operations of two US HealthCare Communications oncology titles—The American Journal of Hematology/Oncology and Oncology Nursing News.

Haymarket Medical's parent company owns MM&M. Terms of the deal were not disclosed.

Haymarket brought on two execs from Quadrant HealthCom to run it. Steven Svec, who was VP/group publisher at Quadrant, will serve as publisher of the titles, and Chad Holloway, an associate publisher at Quadrant, will serve as sales director.

The American Journal of Hematology/Oncology remains a monthly, with a circulation of around 40,000 oncologists, hematology-oncologists and sub-specialists, and will continue to be based in San Diego. Oncology Nursing News will go down to a bimonthly schedule, with a circulation of around 29,000, and will be moved into Haymarket's New York offices.

Haymarket Medical CEO Lee Maniscalco said: “The practical, clinical guidance these peer-reviewed publications offer to their readers and the wide variety of continuing education opportunities they provide throughout the year make this a perfect fit for Haymarket.” It's easy to see why Haymarket wants to play in the oncology space. The category was a rare bright spot in a bleak year for medical journals last year, with cancer therapies, the seventh-most heavily advertised area according to PERQ/HCI.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.